Please ensure Javascript is enabled for purposes of website accessibility

GlycoMimetics-Pfizer accord pays off (access required)

GlycoMimetics Inc., of Gaithersburg, a biopharmaceutical company focused on discovering and developing drugs for human wound healing and tissue repair, said it has received a $15 million payment from Pfizer Inc., under a collaborative agreement between the two companies for the development of rivipansel, a treatment for painful episodic flare-ups of sickle cell disease.